CN101384568B - 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 - Google Patents

乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 Download PDF

Info

Publication number
CN101384568B
CN101384568B CN2007800056683A CN200780005668A CN101384568B CN 101384568 B CN101384568 B CN 101384568B CN 2007800056683 A CN2007800056683 A CN 2007800056683A CN 200780005668 A CN200780005668 A CN 200780005668A CN 101384568 B CN101384568 B CN 101384568B
Authority
CN
China
Prior art keywords
formula
alkyl
hydrogen
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800056683A
Other languages
English (en)
Chinese (zh)
Other versions
CN101384568A (zh
Inventor
Y·G·古
X·徐
M·韦茨伯格
H·沈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN101384568A publication Critical patent/CN101384568A/zh
Application granted granted Critical
Publication of CN101384568B publication Critical patent/CN101384568B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2007800056683A 2006-02-15 2007-02-15 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 Expired - Fee Related CN101384568B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77351406P 2006-02-15 2006-02-15
US60/773,514 2006-02-15
PCT/US2007/062181 WO2007095603A2 (en) 2006-02-15 2007-02-15 Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome

Publications (2)

Publication Number Publication Date
CN101384568A CN101384568A (zh) 2009-03-11
CN101384568B true CN101384568B (zh) 2012-12-12

Family

ID=38330470

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800056683A Expired - Fee Related CN101384568B (zh) 2006-02-15 2007-02-15 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用

Country Status (6)

Country Link
US (1) US8735595B2 (enExample)
EP (1) EP1991536A2 (enExample)
JP (1) JP2009526868A (enExample)
CN (1) CN101384568B (enExample)
CA (1) CA2641766A1 (enExample)
WO (1) WO2007095603A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0608910A2 (pt) 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
JP5369257B2 (ja) * 2006-02-15 2013-12-18 アッヴィ・インコーポレイテッド 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびそれらの糖尿病、肥満および代謝症候群での使用
BRPI0811939A2 (pt) 2007-05-22 2014-11-25 Achillion Pharmaceuticals Inc Tiazóis substituídos por heteroarila
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2297163B1 (en) 2008-05-28 2015-07-08 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
CA2778886C (en) 2009-11-10 2014-01-07 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
PT2621493T (pt) 2010-09-30 2016-11-14 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
PL2632925T3 (pl) 2010-10-29 2015-10-30 Pfizer N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA
EA022375B1 (ru) 2011-04-22 2015-12-30 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ
EP2994138A4 (en) * 2013-05-10 2016-12-28 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
EP2994139B1 (en) 2013-05-10 2019-04-10 Gilead Apollo, LLC Acc inhibitors and uses thereof
JP6417403B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
DK3013813T3 (da) 2013-06-27 2019-06-03 Pfizer Heteroaromatiske forbindelser og anvendelse deraf som dopamin-d1-ligander
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
WO2015056782A1 (ja) 2013-10-17 2015-04-23 塩野義製薬株式会社 新規アルキレン誘導体
JP2016079168A (ja) 2014-10-17 2016-05-16 塩野義製薬株式会社 ９員縮合環誘導体
US10301292B2 (en) 2014-11-26 2019-05-28 Takeda Pharmaceutical Company Limited Bicyclic compound
JP6785223B2 (ja) * 2015-03-31 2020-11-18 武田薬品工業株式会社 単環式化合物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196876A (ja) 1983-04-22 1984-11-08 Sumitomo Chem Co Ltd １，２，４−オキサジアゾ−ル誘導体、その製造法およびそれを有効成分とする除草剤
WO1986003203A1 (fr) 1984-11-22 1986-06-05 Yoshitomi Pharmaceutical Industries, Ltd. Derives de thienylthiazole
CA2044533A1 (en) * 1990-06-29 1991-12-30 Philippe Guerry Substituted aminoalkylbiphenyl derivatives
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
US5962685A (en) 1994-08-02 1999-10-05 Nippon Soda Co., Ltd. Oxazole derivatives, process for producing the same, and herbicide
AU3264695A (en) 1994-08-23 1996-03-14 Nissan Chemical Industries Ltd. Pyridine derivative
DE19536809A1 (de) 1995-10-02 1997-04-03 Basf Ag Heterocyclisch substituierte Salicylsäurederivate
CA2190699A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Tertiary amines
WO1997025319A1 (en) * 1996-01-05 1997-07-17 Novartis Ag Substituted 1,2,4,6-thiatriazines useful as herbicides
AU4618497A (en) 1996-08-27 1998-03-19 Novartis Ag Herbicidal s-substituted 1,2,4,6-thiatriazines
JPH11171848A (ja) * 1997-09-26 1999-06-29 Fujirebio Inc 芳香族アミド誘導体
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US6586453B2 (en) * 2000-04-03 2003-07-01 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
CN1809750A (zh) 2000-12-26 2006-07-26 研究发展基金会 作为脂肪调控和胰岛素作用靶标的乙酰辅酶a羧化酶2
IL159002A0 (en) 2001-06-07 2004-05-12 Lilly Co Eli Modulators of peroxisome proliferator activated receptors (ppar)
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7232838B2 (en) * 2001-08-13 2007-06-19 Janssen Pharmaceutica N.V. 2-amino-4,5-trisubstituted thiazolyl derivatives
JPWO2003026661A1 (ja) * 2001-09-14 2005-01-06 山之内製薬株式会社 インスリン分泌促進剤及び新規なピリミジン誘導体
JP2005162612A (ja) * 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
JP2005529077A (ja) 2002-02-25 2005-09-29 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体調節物質
EP1478437B1 (en) 2002-02-27 2005-08-31 Pfizer Products Inc. Acc inhibitors
BR0316193A (pt) * 2002-12-12 2005-09-27 Galderma Res & Dev Composto, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
JP2005272476A (ja) * 2003-04-09 2005-10-06 Japan Tobacco Inc 複素芳香５員環化合物及びその医薬用途
CA2521830A1 (en) 2003-04-09 2004-10-21 Japan Tobacco Inc. Heteroaromatic pentacyclic compound and medicinal use thereof
DE602004015600D1 (de) 2003-05-27 2008-09-18 Sod Conseils Rech Applic Neue imidazolderivative, deren herstellung und deren verwendung als medikament
CA2529154C (en) 2003-06-20 2013-05-07 Galderma Research & Development, S.N.C. Novel compounds that modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions
GB2404855A (en) 2003-07-07 2005-02-16 Pantherix Ltd Arylcarboxylic acid derivatives and their therapeutic use
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
JP2007500179A (ja) * 2003-07-30 2007-01-11 サイクラセル・リミテッド キナーゼ阻害剤としての２−アミノフェニル−４−フェニルピリミジン
JP2007504229A (ja) * 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
WO2005044793A2 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
US20080207685A1 (en) 2003-11-20 2008-08-28 Eli Lilly And Company Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar
WO2005058876A1 (en) * 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases
CA2551610A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
CN1968922A (zh) 2004-06-18 2007-05-23 米伦纽姆医药公司 因子xa抑制剂
US20050288340A1 (en) 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
JP2006022065A (ja) 2004-07-09 2006-01-26 Dai Ichi Seiyaku Co Ltd カルバメート誘導体
CA2575411A1 (en) * 2004-07-27 2006-02-02 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
US20090196912A1 (en) * 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
US7645778B2 (en) * 2005-01-19 2010-01-12 Bristol-Myers Squibb Company Heteroaryl compounds as P2Y1 receptor inhibitors
JP5369257B2 (ja) 2006-02-15 2013-12-18 アッヴィ・インコーポレイテッド 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびそれらの糖尿病、肥満および代謝症候群での使用
EP1996567B1 (en) 2006-02-15 2013-09-18 AbbVie Inc. Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
US7928243B2 (en) 2006-12-21 2011-04-19 Abbott Laboratories Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
IN2009KN04568A (enExample) 2007-06-01 2015-08-28 Univ Princeton

Also Published As

Publication number Publication date
WO2007095603A2 (en) 2007-08-23
EP1991536A2 (en) 2008-11-19
WO2007095603A3 (en) 2008-03-13
CN101384568A (zh) 2009-03-11
JP2009526868A (ja) 2009-07-23
CA2641766A1 (en) 2007-08-23
US8735595B2 (en) 2014-05-27
US20070219251A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
CN101384568B (zh) 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
JP5291471B2 (ja) 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
US8748627B2 (en) Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
US7928243B2 (en) Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2007019251A9 (en) Sphingosine kinase inhibitors and methods of their use
EP0934290B1 (fr) Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
HRP20040810A2 (en) Thiazole and oxazole derivatives that modulate ppar activity
CA2712962A1 (en) Thiazole derivative and use thereof as vap-1 inhibitor
KR20100051812A (ko) 3-위치에서 이치환된 인돌-2-온 유도체, 그의 제조 및 그의 치료적 용도
ES2220504T3 (es) Derivados del aminotiazol y su uso como ligandos receptores de crf.
JP5410969B2 (ja) ２，４，５−三置換チアゾール化合物、それを含有する医薬組成物、並びにその調製及び医学的使用
JP4550353B2 (ja) 造血器型プロスタグランジンｄ２合成酵素阻害剤
US20060178400A1 (en) Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
MX2008010469A (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
CN104245694B (zh) 具有治疗活性的氨基亚甲基吡唑啉酮
MX2008010471A (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO1995018121A1 (en) Novel benzylamine derivative
MX2008010467A (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2002036547A1 (en) Cyclopropanecarboxylic acid amide compounds and medicinal use thereof
JPWO2006126581A1 (ja) 組合せ医薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130619

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130619

Address after: Illinois State

Patentee after: ABBVIE company

Address before: Illinois State

Patentee before: Abbott GmbH. & Co. Kg

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121212

Termination date: 20140215